Sharon Shacham Biography and Net Worth

Dr. Shacham co-founded Karyopharm in 2008 and has served as our Chief Scientific Officer since December 2012. She was also President of Research and Development from December 2012 to April 2021. From 2010 to 2012, Dr. Shacham served as our Chief Scientific Officer and Head of Research and Development, and prior to that, as our President and Chief Executive Officer. Dr. Shacham has led our scientific progress since inception.

Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led the company’s efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials.

Dr. Shacham holds a Bachelor of Science in Chemistry, a Doctor of Philosophy in Chemistry, and a Master of Business of Administration from Tel Aviv University.

What is Sharon Shacham's net worth?: The estimated net worth of Sharon Shacham is at least $1.00 million as of March 18th, 2021. Dr. Shacham owns 920,152 shares of Karyopharm Therapeutics stock worth more than $1,002,966 as of April 23rd. This net worth approximation does not reflect any other investments that Dr. Shacham may own. Additionally, Dr. Shacham receives an annual salary of $1,400,000.00 as Insider at Karyopharm Therapeutics. Learn More about Sharon Shacham's net worth.
How old is Sharon Shacham?: Dr. Shacham is currently 54 years old. There are 6 older executives and no younger executives at Karyopharm Therapeutics. Learn More on Sharon Shacham's age.
What is Sharon Shacham's salary?: As the Insider of Karyopharm Therapeutics Inc., Dr. Shacham earns $1,400,000.00 per year. Learn More on Sharon Shacham's salary.
How do I contact Sharon Shacham?: The corporate mailing address for Dr. Shacham and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Sharon Shacham's contact information.
Has Sharon Shacham been buying or selling shares of Karyopharm Therapeutics?: Sharon Shacham has not been actively trading shares of Karyopharm Therapeutics during the last ninety days. Most recently, Sharon Shacham sold 6,707 shares of the business's stock in a transaction on Monday, February 7th. The shares were sold at an average price of $9.86, for a transaction totalling $66,131.02. Learn More on Sharon Shacham's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Michael Kauffman (Director), Michael Mason (CFO), Stephen Mitchener (SVP), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, Karyopharm Therapeutics insiders bought shares 1 times. They purchased a total of 41,140 shares worth more than $50,190.80. During the last twelve months, insiders at the sold shares 23 times. They sold a total of 220,227 shares worth more than $278,847.52. The most recent insider tranaction occured on April, 22nd when EVP Reshma Rangwala sold 6,789 shares worth more than $7,943.13. Insiders at Karyopharm Therapeutics own 3.3% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 4/22/2024.

Sharon Shacham Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/7/2022	Sell	6,707	$9.86	$66,131.02
3/18/2021	Sell	4,000	$12.39	$49,560.00	920,152
2/18/2021	Sell	9,495	$14.83	$140,810.85	776,452
7/10/2020	Sell	15,000	$19.27	$289,050.00
6/10/2020	Sell	15,000	$16.60	$249,000.00
3/9/2020	Sell	10,000	$22.52	$225,200.00	766,489
11/11/2019	Sell	20,000	$15.60	$312,000.00
11/1/2019	Sell	10,000	$12.00	$120,000.00	741,134
9/16/2019	Sell	20,000	$12.00	$240,000.00
1/7/2019	Sell	12,500	$10.23	$127,875.00
12/7/2018	Sell	12,500	$10.11	$126,375.00	726,010
11/19/2018	Sell	400	$11.14	$4,456.00	512,543
11/7/2018	Sell	12,500	$11.65	$145,625.00	726,010
10/18/2018	Sell	10,000	$12.63	$126,300.00	713,510
10/8/2018	Sell	12,500	$15.75	$196,875.00	715,274
9/7/2018	Sell	12,500	$19.31	$241,375.00	726,010
7/9/2018	Sell	12,500	$18.72	$234,000.00	726,010
6/18/2018	Sell	10,000	$18.66	$186,600.00	713,510
6/7/2018	Sell	10,000	$17.30	$173,000.00
5/7/2018	Sell	10,000	$16.77	$167,700.00
4/9/2018	Sell	10,000	$12.48	$124,800.00	723,510
3/7/2018	Sell	10,000	$16.15	$161,500.00	723,510
2/7/2018	Sell	10,000	$12.50	$125,000.00	723,510
1/8/2018	Sell	10,000	$10.08	$100,800.00	723,510
12/7/2017	Sell	10,000	$10.39	$103,900.00
1/12/2015	Sell	25,000	$33.00	$825,000.00
6/18/2014	Sell	20,000	$41.76	$835,200.00

Sharon Shacham Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $1.09

$1.08

$1.17

50 Day Range

MA: $1.34

$1.10

$1.58

2 Week Range

Now: $1.09

$0.62

$4.11

Volume

1,591,056 shs

Average Volume

1,654,813 shs

Market Capitalization

$125.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

Sharon Shacham Biography and Net Worth

What is Sharon Shacham's net worth?

How old is Sharon Shacham?

What is Sharon Shacham's salary?

How do I contact Sharon Shacham?

Has Sharon Shacham been buying or selling shares of Karyopharm Therapeutics?

Who are Karyopharm Therapeutics' active insiders?

Are insiders buying or selling shares of Karyopharm Therapeutics?